ESMO 2025 – Drs Ma & LeVasseur on CDK4/6 Data

Drs. Kim Ma and Nathalie LeVasseur review and discuss adjuvant CDK4/6 inhibitor data presented on Day 1 of ESMO 2025, highlighting key updates from monarchE and NATALEE trials and how these findings may influence patient care in early breast cancer.